- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04344210
Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus
Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial
INTRODUCTION In critical situations, such as the current COVID 19 pandemic, themes of fear, uncertainty and stigmatization are common and constitute barriers to appropriate medical and mental health interventions. These challenges, when faced by those who live with a chronic disease, such as diabetes mellitus (DM), can negatively influence quality of life and adherence to treatment, compromising the control of the disease.
OBJECTIVES The present study aims to investigate the effectiveness of a tele-intervention during the COVID-19 pandemic in improving glycemic control, lipid profile, blood pressure levels and parameters of medication adherence, mental well-being and sleep quality in patients with type 1 DM and type 2 DM.
METHODS A randomized clinical trial will be carried out with patients with a previous diagnosis of type 1 DM and type 2 DM, who are registered at the Hospital de Clínicas de Porto Alegre (HCPA). Inclusion criteria will be age greater than or equal to 18 years, collection of HbA1c in the HCPA laboratory in January, February or March 2020 and availability to receive weekly phone calls. Patients will be randomized, stratified by type of diabetes, in two groups: G1: participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the social distancing period ; G2: participants will receive the usual care. The primary outcome assessed will be the variation in HbA1c levels comparatively between groups, with or without a tele-guided strategy, after four months of social distancing (or as long as the recommendation of social distancing measures remains). Secondary outcomes will include experiencing confirmation of COVID-19 infection, variation in lipid profile, blood pressure levels and variation in parameters of emotional distress related to diabetes, eating disorders, medication adherence, symptoms minor psychiatric disorders and altered sleep patterns, which will be evaluated with specific and validated scales. According to the sample calculation, 150 patients will be included in the study (92 with type 2 DM and 58 with type 1 DM). Analysis by intention to treat will be performed separately for patients with type 1 DM and with type 2 DM.
SCHEDULE The proposed experiment will start immediately after approval of this project by the research ethics committee. The duration of the proposed intervention is 4 months (or as long as the recommendation of social distancing measures remains. This means that the study may be completed before or after that period, based on national recommendations for social distancing in Brazil), with a data analysis plan and publication of the results until September 2020.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brésil, 90620-170
- Hospital de Clinicas de Porto Alegre
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Type 1 diabetes mellitus or type 2 diabetes mellitus;
- Age greater than or equal to 18 years;
- HbA1c assessed in January, February or March 2020;
- Availability to receive weekly phone calls
Exclusion Criteria:
- Any severe cognitive limitation that prevents the necessary interaction to carry out this study (advanced dementia, deafness, dysarthria, aphasia);
- Do not present a telephone record in an electronic medical record;
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Tele-Intervention
Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
|
Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
|
|
Aucune intervention: Usual Care
Participants will receive the usual care
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Variation in HbA1c levels
Délai: 4 months (or as long as the recommendation of social distancing measures remains)
|
Variation in HbA1c levels comparatively between groups after the period of social distancing measures.
|
4 months (or as long as the recommendation of social distancing measures remains)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
COVID-19 infection
Délai: 4 months (or as long as the recommendation of social distancing measures remains)
|
Confirmation of coronavirus infection by rapid test
|
4 months (or as long as the recommendation of social distancing measures remains)
|
|
Variation in lipid profile
Délai: 4 months (or as long as the recommendation of social distancing measures remains)
|
Comparison of the lipid profile of the last year with the lipid profile after the intervention between the groups.
|
4 months (or as long as the recommendation of social distancing measures remains)
|
|
Variation in blood pressure levels
Délai: 4 months (or as long as the recommendation of social distancing measures remains)
|
Comparison of the blood pressure level of the last consultation with the pressure after the intervention between the groups.
|
4 months (or as long as the recommendation of social distancing measures remains)
|
|
Comparison of emotional distress associated with the routine of living with diabetes after intervention between groups
Délai: 4 months (or as long as the recommendation of social distancing measures remains)
|
Evaluation of emotional distress associated with the routine of living with diabetes - B-PAID (Brazilian Problem Areas In Diabetes Scale)
|
4 months (or as long as the recommendation of social distancing measures remains)
|
|
Comparison of eating disorders between groups
Délai: 4 months (or as long as the recommendation of social distancing measures remains)
|
Evaluation of eating disorders - EAT - 26 SCALE (Teste de Atitudes Alimentares)
|
4 months (or as long as the recommendation of social distancing measures remains)
|
|
Comparison of adherence to the proposed clinical treatment between groups
Délai: 4 months (or as long as the recommendation of social distancing measures remains)
|
Evaluation of adherence to the proposed clinical treatment - SCI R (Self-Care Inventory - revised)
|
4 months (or as long as the recommendation of social distancing measures remains)
|
|
Comparison of minor psychiatric disorders between groups
Délai: 4 months (or as long as the recommendation of social distancing measures remains)
|
Evaluation of minor psychiatric disorders - SRQ 20 (Self Report Questionnaire)
|
4 months (or as long as the recommendation of social distancing measures remains)
|
|
Comparison of sleep pattern changes between groups
Délai: 4 months (or as long as the recommendation of social distancing measures remains)
|
Evaluation of sleep pattern changes - MSQ (Mini Sleep Questionnaire)
|
4 months (or as long as the recommendation of social distancing measures remains)
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Alessi J, Becker AS, Amaral B, de Oliveira GB, Franco DW, Knijnik CP, Kobe GL, de Brito A, de Carvalho TR, Telo GH, Schaan BD, Telo GH. Type 1 diabetes and the challenges of emotional support in crisis situations: results from a feasibility study of a multidisciplinary teleintervention. Sci Rep. 2022 May 20;12(1):8526. doi: 10.1038/s41598-022-12227-z.
- Alessi J, Becker AS, Amaral B, de Oliveira GB, Franco DW, Knijnik CP, Kobe GL, de Brito A, de Carvalho TR, Telo GH, Schaan BD, Telo GH. Type 1 diabetes and the challenges of emotional support in crisis situations: results from a randomized clinical trial of a multidisciplinary teleintervention. Sci Rep. 2022 Feb 23;12(1):3086. doi: 10.1038/s41598-022-07005-w.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Troubles du métabolisme du glucose
- Maladies métaboliques
- Infections à coronavirus
- Infections à Coronaviridae
- Infections à Nidovirales
- Infections par virus à ARN
- Maladies virales
- Infections
- Infections des voies respiratoires
- Maladies des voies respiratoires
- Maladies du système immunitaire
- Maladies auto-immunes
- Pneumonie virale
- Pneumonie
- Maladies pulmonaires
- Maladies du système endocrinien
- COVID-19 [feminine]
- Diabète sucré
- Diabète sucré, Type 2
- Diabète sucré, type 1
Autres numéros d'identification d'étude
- 2020241093
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- ANALYTIC_CODE
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .